UOC
TLSIW icon

UBS O'Connor’s TriSalus Life Sciences Warrant TLSIW Stock Holding History

UBS O'Connor’s Portfolio TLSIW Stock Details TLSIW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-66,664
Closed -$56K – 1009
2021
Q3 		$56K Hold
66,664
– – ﹤0.01% 878
2021
Q2 		$67K Hold
66,664
– – ﹤0.01% 856
2021
Q1 		$78K Buy
+66,664
New +$120K ﹤0.01% 777

Other funds holding TLSIW

RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
AGC
Angelo Gordon & Co New York $1.06B AUM 47.95% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
GL
Governors Lane New York $1.56B AUM 30.42% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

UBS O'Connor's TLSIW Position: Q4 2021 in Review

UBS O'Connor sold out of TriSalus Life Sciences Warrant (TLSIW) in Q4 2021, closing a stake of 66,664 shares — an estimated $56K sold.

UBS O'Connor first reported a position in TLSIW in Q1 2021 and held it in 3 quarters. The position peaked at $78K in Q1 2021. 30 funds tracked by Wall St. Rank hold TLSIW as of Q4 2021.

  • UBS O'Connor reported no remaining TriSalus Life Sciences Warrant position as of Q4 2021 after selling out during the quarter.
  • UBS O'Connor sold 66,664 TriSalus Life Sciences Warrant shares in Q4 2021, an estimated $56K.
  • UBS O'Connor first reported a position in TriSalus Life Sciences Warrant in Q1 2021 and held it in 3 quarters.
  • UBS O'Connor's TriSalus Life Sciences Warrant position peaked at $78K in Q1 2021.
  • 30 funds tracked by Wall St. Rank held TriSalus Life Sciences Warrant as of Q4 2021.

Based on UBS O'Connor's 13F filing for Q4 2021, filed 14 Feb 2022.